Instalab
Login

What Type of Cancer Causes Low Hemoglobin?

Anemia, defined as low levels of hemoglobin in the blood, is one of the most common complications seen in patients with cancer. While anemia itself can arise from many causes, including chronic disease, nutritional deficiencies, or bleeding, it is particularly prevalent in cancer patients, either as a direct effect of the malignancy or as a side effect of treatment.

Understanding the types of cancer most strongly associated with low hemoglobin levels is essential, as anemia can significantly impact patient outcomes, quality of life, and survival.
Instalab Research

The Link Between Cancer and Hemoglobin Levels

Cancer disrupts hemoglobin levels through several mechanisms. Tumor growth may cause internal bleeding, bone marrow suppression, or nutritional deficiencies. Additionally, chemotherapy and radiotherapy often impair red blood cell production, further compounding anemia. Evidence shows that hemoglobin decline can precede diagnosis in some cancers, making it an early signal of malignant disease.

Cancers Frequently Associated with Low Hemoglobin

Research indicates that not all cancers affect hemoglobin levels equally. Certain malignancies are strongly correlated with anemia due to their biological and clinical characteristics.

  • Blood-Related Cancers: Hematologic malignancies such as leukemias and lymphomas are among the most closely linked to declining hemoglobin levels. Because these cancers originate in bone marrow or lymphatic tissues, they directly interfere with the body’s ability to produce red blood cells. Studies show significant hemoglobin decline before diagnosis in lymphatic leukemia and Hodgkin lymphoma.
  • Gastrointestinal Cancers: Stomach and colon cancers frequently cause anemia, largely due to chronic bleeding in the digestive tract. Declines in hemoglobin can begin years before diagnosis, making anemia one of the earliest clinical clues for these malignancies.
  • Ovarian Cancer: Ovarian cancer patients often develop anemia both before and during chemotherapy. Hemoglobin levels below 12 g/dL are strongly associated with reduced overall survival, highlighting anemia as a prognostic factor in ovarian cancer outcomes.
  • Lung Cancer: Low hemoglobin levels are common in lung cancer and serve as an independent predictor of poor survival. More than half of lung cancer patients present with anemia at diagnosis, and survival rates are significantly reduced in those with low hemoglobin.
  • Breast Cancer: Breast cancer is also linked with anemia, particularly due to treatment-related effects. Hypoxia within the tumor microenvironment contributes to declining hemoglobin levels, and low hemoglobin has been associated with poorer prognosis and reduced treatment efficacy.
  • Cervical and Head & Neck Cancers: In cervical cancer, low hemoglobin levels independently predict worse treatment outcomes with radiotherapy and chemotherapy. Similarly, patients with head and neck cancers who develop anemia during treatment have significantly lower survival rates, especially when combined with prolonged treatment times.
  • Melanoma and Prostate Cancer: Cutaneous malignant melanoma has been linked to low hemoglobin, particularly in patients with nodal involvement and metastatic disease, though anemia is not always an independent prognostic factor. Prostate cancer patients undergoing radiotherapy also experience significant drops in hemoglobin, emphasizing the need for monitoring during treatment.

Why Anemia Matters in Cancer

Low hemoglobin in cancer patients is not merely a side effect. It plays a critical role in patient survival and treatment outcomes. Anemia reduces oxygen delivery to tissues, creating tumor hypoxia, which diminishes the effectiveness of radiation and chemotherapy. Clinical studies consistently show that correcting anemia, when possible, improves both quality of life and survival prospects.

The Role of Hemoglobin in Cancer Care

Low hemoglobin is a hallmark of many cancers, particularly those of the blood, gastrointestinal system, ovaries, lungs, breast, cervix, and head and neck. It often signals disease severity, influences treatment outcomes, and worsens survival if left unaddressed. Monitoring and managing anemia in cancer care is therefore essential, not only to improve comfort and quality of life but also to enhance treatment success and survival.

Since low hemoglobin can be an early sign of cancer or other health conditions, getting tested is a proactive way to protect your health. A Complete Blood Count (CBC) with Differential is a simple lab test that evaluates your red and white blood cells, hemoglobin, and platelets. It helps detect anemia, infections, and inflammation while providing important insight into your overall health.

References
  • Belle, S. (2004). What is the value of hemoglobin as a prognostic and predictive factor in cancer. Ejc Supplements, 2, 11-19. https://doi.org/10.1016/S1359-6349(03)00103-4.
  • Chen, X., Zhou, H., & Lv, J. (2024). The Importance of Hypoxia-Related to Hemoglobin Concentration in Breast Cancer.. Cell biochemistry and biophysics. https://doi.org/10.1007/s12013-024-01386-7.
  • Edgren, G., Bagnardi, V., Bellocco, R., Hjalgrim, H., Rostgaard, K., Melbye, M., Reilly, M., Adami, H., Hall, P., & Nyren, O. (2009). Pattern of declining hemoglobin concentration before cancer diagnosis. International Journal of Cancer, 127. https://doi.org/10.1002/ijc.25122.
  • Mendes, J., Lopes, L., De Castro Sbano, L., Malvão, R., Franca, G., Penna, A., Moreira, A., Cardoso, A., Nogueira, C., Júnior, R., & Franca, C. (2024). The haemoglobin levels of patients with prostate cancer treated with radical radiotherapy. South Florida Journal of Health. https://doi.org/10.46981/archv5n1-011.
  • Münstedt, K., Kovačić, M., Zygmunt, M., & Von Georgi, R. (2003). Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer.. International journal of oncology, 23 3, 837-43 . https://doi.org/10.3892/IJO.23.3.837.
  • Su, N., Liu, C., Leu, Y., Lee, J., Chen, Y., & Chang, Y. (2015). Prolonged radiation time and low nadir hemoglobin during postoperative concurrent chemoradiotherapy are both poor prognostic factors with synergistic effect on locally advanced head and neck cancer patients. OncoTargets and therapy, 8, 251 - 258. https://doi.org/10.2147/OTT.S70204.
  • Tas, F., & Erturk, K. (2018). Anemia in Cutaneous Malignant Melanoma: Low Blood Hemoglobin Level is Associated with Nodal Involvement, Metastatic Disease, and Worse Survival. Nutrition and Cancer, 70, 236 - 240. https://doi.org/10.1080/01635581.2018.1412475.
  • Xu, D. (2019). Changes of hemoglobin levels after chemotherapy in patients with ovarian cancer and influence of anemia on prognosis. , 21, 876-879. https://doi.org/10.3760/CMA.J.ISSN.1008-1372.2019.06.017.
  • Zhang, D., Wang, J., Mayr, N., Montebello, J., & Yuh, W. (2007). WE‐D‐M100J‐07: Impact of Hemoglobin On Outcome of Chemo/Radiation Therapy for Cervical Cancer. Medical Physics, 34, 2603-2603. https://doi.org/10.1118/1.2761568.